The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: Observations from a prospective study in men undergoing intermittent androgen suppression

Journal of Urology

Volumn 187, Issue 6, 2012, Pages 2162-2167

  Ng, Evan ^a   Woo, Henry H ^b   Turner, Sandra ^c   Leong, Eugene ^a   Jackson, Melanie ^a   Spry, Nigel ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

androgens; flutamide; leuprolide; prostatic neoplasms; sexual behavior

Indexed keywords

FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; AUSTRALIA; COHORT ANALYSIS; CONVALESCENCE; ERECTILE DYSFUNCTION; HUMAN; LIBIDO; MAJOR CLINICAL STUDY; MALE; MASCULINITY; OBSERVATIONAL STUDY; PENIS ERECTION; PERCEPTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; SEXUAL BEHAVIOR; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION;

EID: 84861094048     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.01.080     Document Type: Article

References (15)

1. A. Jemal, T. Murray, A. Samuels Cancer statistics, 2003 CA Cancer J Clin 53 2003 5
2. AIHW (Australian Institute of Health and Welfare) and AACR (Australasian Association of Cancer Registries) Cancer in Australia: an overview, 2006 Cancer series no. 37., Cat no. CAN 32 2007 AIHW Canberra
3. J.W. Moul Prostate specific antigen only progression of prostate cancer J Urol 163 2000 1632
4. M.H. Rashid, U.B. Chaudhary Intermittent androgen deprivation therapy for prostate cancer Oncologist 9 2004 295
5. M. Pether, S.L. Goldenberg, K. Bhagirath Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience Can J Urol 10 2003 1809
6. T.I. Hwang, H.C. Lo, T.F. Tsai Association among hypogonadism, quality of life and erectile function in middle-aged and aged male in Taiwan Int J Impot Res 19 2007 69
7. N. Spry, L. Kristjanson, B. Hooton Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer Eur J Cancer 42 2006 1083
8. N.A. Spry, D.A. Galvao, R. Davis Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study BJU Int 104 2009 806
9. N. Sato, K. Akaura, S. Isaka Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicentre study Urology 64 2004 341
10. G. Shaw, P. Wilson, J. Cuzick International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients BJU Int 99 2007 1056
11. H. Green, K. Pakenham, B. Headley Quality of life compared during pharmacological treatments and clinical monitoring for non-localised prostate cancer: a randomised controlled trial BJU Int 93 2004 975
12. S. Turner, K. Adams, C. Bull Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation Urology 54 1999 124
13. M. Gacci, G. Corona, G. Apolone Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer Prostate Cancer Prostatic Dis 13 2010 168
14. A. Potosky, K. Knopf, L. Clegg Quality-of-life outcome after primary androgen deprivation therapy: results from the prostate cancer outcomes study J Clin Oncol 19 2001 3750
15. R.C. Rosen, A. Riley, G. Wagner The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction Urology 49 1997 822